CDSCO panel nod to Hetero lab to study Pregabalin, Polmacoxib FDC tablet - Video
|
Overview
The drug major Hetero Labs has got approval from the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) to conduct a bioequivalence (BE) study and Phase III clinical trial of fixed-dose combination (FDC) pregabalin extended released 82.5mg plus polmacoxib 2mg tablet for treating moderate acute, chronic or neuropathic pain.
However, this approval is subject to a condition that the firm should initiate the phase III clinical trial only after submitting the study results of the BE study.
For more details, check out the link given below:
Hetero Lab Gets CDSCO Panel Nod To Study Pregabalin, Polmacoxib FDC Tablet
Speakers
Isra Zaman
B.Sc Life Sciences, M.Sc Biotechnology, B.Ed
Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at editorial@medicaldialogues.in.
